Biobytes steps up efforts to seize global sarcopenia market following entering into MOU with Canadian MDx firm

[SWTV 이지한 기자] Biobytes announced that it is expanding into the global market in earnest after signing an MOU and NDA with a Canadian MDx firm.

Biobytes, a company which specializes in drug biomarker discovery and development leveraging a sarcopenia biobank cohort database, has a history of collaborating with Hyundai Engineering and Construction by participating in Seoul Startup Hub Gongdoek Open Innovation Program. Accumulating experience of conducting PoC with a large enterprise and achieving commercialization linkage provided a solid foundation for the company to form strategic partnerships for global expansion.

By leveraging Biobytes’ AI-driven Sarco-Finding technology to analyze patients’ blood and tissue, combined with patients’ sarcopenia biospecimens provided by the Canadian MDx firm, the company aims to introduce next-generation solution for sarcopenia diagnosis and treatment.

The partnership offered opportunities for Biobytes to expand Muscle Bank, the world’s first multi-center sarcopenia biobank cohort database, which is currently under development, to the global market. It is expected to generate clinically meaningful evidence that ensures global market adoption.

Lee Jung-woo, the CEO of Biobytes noted, “Beyond a mere technology exchange, this partnership will serve as a pivotal turning point to offer global standard for MDx industry. We are committed to developing a breakthrough treatment for sarcopenia through leveraging data and analysis technology of both companies”

Biobytes has been recognized for its various innovations across diverse sectors, including AI-driven medical devices for Mdx diagnostic support and functional nutrition for enhancing muscle strength. The company is leading the market as it can calculate the risk of sarcopenia in less than a minute.

For the first time of the world, it is building multi-center sarcopenia biobank cohort database by collaborating with various medical institutions including Wonju Severance Christian Hospital, Kang Buk Samsung Hospital, and Seoul St. Mary's Hospital. Building on this comprehensive database, the company developed sarco-finding, an AI driven sarcopenia drug biomarker discovery platform. It has now initiated preparations for the technology transfer of 10 identified sarcopenia drug biomarkers.